[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112022007729A2 - Polipeptídeo tendo efeito mmp2-inibidor - Google Patents

Polipeptídeo tendo efeito mmp2-inibidor

Info

Publication number
BR112022007729A2
BR112022007729A2 BR112022007729A BR112022007729A BR112022007729A2 BR 112022007729 A2 BR112022007729 A2 BR 112022007729A2 BR 112022007729 A BR112022007729 A BR 112022007729A BR 112022007729 A BR112022007729 A BR 112022007729A BR 112022007729 A2 BR112022007729 A2 BR 112022007729A2
Authority
BR
Brazil
Prior art keywords
polypeptide
mmp2
inhibitor effect
effect
inhibitor
Prior art date
Application number
BR112022007729A
Other languages
English (en)
Inventor
Hayashi Masato
Takeuchi Tomoki
Nomura Yusaku
Tamita Tomoko
Shimono Rie
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of BR112022007729A2 publication Critical patent/BR112022007729A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

POLIPEPTÍDEO TENDO EFEITO MMP2-INIBIDOR. A presente invenção provê um polipeptídeo substituído ou um sal farmaceuticamente aceitável do mesmo com um efeito para inibir MMP2, o polipeptídeo substituído representado pela fórmula [I']: [I']
BR112022007729A 2019-11-08 2020-11-06 Polipeptídeo tendo efeito mmp2-inibidor BR112022007729A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019203338 2019-11-08
PCT/JP2020/042350 WO2021090959A1 (ja) 2019-11-08 2020-11-06 Ｍｍｐ２阻害作用を有するポリペプチド

Publications (1)

Publication Number Publication Date
BR112022007729A2 true BR112022007729A2 (pt) 2022-07-12

Family

ID=75849183

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007729A BR112022007729A2 (pt) 2019-11-08 2020-11-06 Polipeptídeo tendo efeito mmp2-inibidor

Country Status (13)

Country Link
US (1) US20240199692A1 (pt)
EP (1) EP4056581A4 (pt)
JP (1) JPWO2021090959A1 (pt)
KR (1) KR20220093087A (pt)
CN (1) CN114450294A (pt)
AU (1) AU2020380902A1 (pt)
BR (1) BR112022007729A2 (pt)
CA (1) CA3160310A1 (pt)
IL (1) IL292684A (pt)
MX (1) MX2022005440A (pt)
TW (1) TW202132327A (pt)
WO (1) WO2021090959A1 (pt)
ZA (1) ZA202205158B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023204170A1 (ja) * 2022-04-18 2023-10-26 大正製薬株式会社 Ｍｍｐ２阻害作用を有する化合物を有効成分として含有する肺の炎症及び線維症の予防又は治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
GB201110938D0 (en) * 2011-06-27 2011-08-10 Iti Scotland Ltd Compounds
KR101363455B1 (ko) * 2011-09-09 2014-02-21 (주)케어젠 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
KR101744959B1 (ko) * 2014-12-05 2017-06-12 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
JPWO2021090959A1 (pt) 2021-05-14
IL292684A (en) 2022-07-01
US20240199692A1 (en) 2024-06-20
TW202132327A (zh) 2021-09-01
CA3160310A1 (en) 2021-05-14
MX2022005440A (es) 2022-05-30
KR20220093087A (ko) 2022-07-05
CN114450294A (zh) 2022-05-06
WO2021090959A1 (ja) 2021-05-14
EP4056581A4 (en) 2023-11-29
ZA202205158B (en) 2023-11-29
AU2020380902A1 (en) 2022-05-26
EP4056581A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
BR112022012585A2 (pt) Inibidores de formas mutantes de egfr
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
BR112022025613A2 (pt) Novo inibidor de secreção de ácido e uso do mesmo
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
ZA202206923B (en) New methylquinazolinone derivatives
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112014009108A2 (pt) derivado heterocíclico tendo atividade antagonista de receptor de pgd2
BR112023015359A2 (pt) Composto de pirimidopirano
BR112015009032A2 (pt) inibidores de agrecanase
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
BR112022002648A2 (pt) Sal
BR112013018938A2 (pt) agente antifúngico tópico
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
BR112022007729A2 (pt) Polipeptídeo tendo efeito mmp2-inibidor
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
BR112023026964A2 (pt) Composto de sulfoximina e uso do mesmo